Apixaban versus warfarin for primary thromboprophylaxis in patients with multiple myeloma undergoing immunomodulatory treatment

Authors

Yu-Cheng Chang, Department of Medicine, Danbury Hospital, Danbury, CT
Cho-Han Chiang, Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts, USA
Zhiting Tang, Rochester Regional HealthFollow
Xin Ya See, Rochester Regional HealthFollow
Cho-Hung Chiang, National Taiwan University Hospital, Taipei, Taiwan
Kuan-Yu Chi, Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY
Yu Chang, National Cheng Kung University College of Medicine, Tainan, Taiwan
Wenli Gao, Praxair Cancer Center Danbury Hospital, Danbury, CT

Department

Internal Medicine

Document Type

Conference Proceeding

Publication Title

Journal of Clinical Oncology

Conference Name

American Society of Clinical Oncology (ASCO) Annual Meeting

Conference Date

2024-05-31 - 2024-06-04

First Page

7548

DOI

10.1200/JCO.2024.42.16_suppl.7548

Volume

42

Issue

16_suppl

Publication Date

6-1-2024

Recommended Citation

Chang, Y., Chiang, C., Tang, Z., See, X., Chiang, C., Chi, K., Chang, Y., & Gao, W. (2024). Apixaban versus warfarin for primary thromboprophylaxis in patients with multiple myeloma undergoing immunomodulatory treatment. Journal of Clinical Oncology, 42 (16_suppl), 7548. https://doi.org/10.1200/JCO.2024.42.16_suppl.7548